Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
Peibin Yue(University of Central Florida), James Turkson(Cedars-Sinai Medical Center), Simoun Mikhael(Cedars-Sinai Medical Center), Felix Alonso-Valenteen(Cedars-Sinai Medical Center), Kathleen M. Kershaw(Cedars-Sinai Medical Center), Francisco Lopez‐Tapia(Cedars-Sinai Medical Center), Maria Celeridad(Sanford Burnham Prebys Medical Discovery Institute), Nicholas D. P. Cosford(Discovery Institute), Christine Brotherton‐Pleiss(University of Hawaiʻi at Mānoa), Lali K. Medina‐Kauwe(Cedars-Sinai Medical Center), Yinsong Zhu(Cedars-Sinai Medical Center), Kayo Nakamura(University of Hawaiʻi at Mānoa), Marcus A. Tius(University of Hawaiʻi at Mānoa), Jasmine Chen(University of Hawaiʻi at Mānoa), Stephen L. Shiao(Cedars-Sinai Medical Center), Douglas J. Sheffler(Sanford Burnham Prebys Medical Discovery Institute), Nagendra Verma(St. Cloud State University), Wen‐Zhen Fu(Zhengzhou University), Yue Chen(Cedars-Sinai Medical Center), Songqin Pan(University of California, Riverside), Weiliang Chen(University of Hawaiʻi at Mānoa), Allison S. Limpert(Sanford Burnham Prebys Medical Discovery Institute)
Cited by 21
Related Papers
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
|Molecular Cell|2006|1.5k
Acetylation Is Indispensable for p53 Activation
|Cell|2008|828
STAT3 as a target for inducing apoptosis in solid and hematological tumors
|Cell Research|2008|489
Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation
|Journal of Biological Chemistry|2001|437
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
|Proceedings of the National Academy of Sciences|2012|347